Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

More efficient mobilisation of peripheral blood stem cells with HiDAC plus AMSA plus G-CSF than with mini-ICE plus G-CSF in patients with AML

In English

Författare

  • M Hoglund
  • M Brune
  • Bengt Sallerfors
  • T Ahlgren
  • R Billström
  • M Hedenus
  • B Markevarn
  • B Nilsson
  • B Simonsson
  • D Stockelberg
  • A Wahlin
Visa allt

Summary, in English

We have compared the efficacy of two PBSC mobilisation regimens, mini-ICE + filgrastim (second consolidation) and HiDAC + AMSA + filgrastim (third consolidation), in two consecutive cohorts of patients with AML CR1 receiving treatment according to a joint protocol. Group A: 18 patients, aged 41 (21-65) years, were mobilised with mini-ICE (idarubicin 8 mg/m(2) + cytarabine 800 mg/m(2) + etoposide 150 mg/m(2) days 1-3) followed by filgrastim 300-480 mug once daily s.c. from day 11 after start of chemotherapy. Only four patients reached >5 CD34+ cells/mul blood (B-CD34+) and were able to undergo leukaphereses. Two out of 18 (11%) reached the defined target of greater than or equal to2.0 x 10(6) CD34+ cells/kg after 1-3 leukaphereses. Group B: 20 patients, aged 50 (29-67) years, received HiDAC + AMSA (cytarabine 3 g/m(2) b.i.d. days 1, 3, 5 + amsacrine 150 mg/m(2) q.d. days 2, 4) followed by filgrastim at a similar dose starting on day 7. A total of 18 patients reached B-CD34+ >5/mul and underwent PBSC harvesting, starting on day 23 (14-29) and yielding 4.0 (0.9-21) x 10(6) CD34+ cells/kg. Of 20 patients, 17 (85%) reached the defined target of greater than or equal to2.0 x 10(6) CD34+ cells/kg after 1-3 leukaphereses. We conclude that wHiDAC + AMSA + G-CSF - in contrast to mini-ICE + G-CSF - is an efficient regimen for mobilising PBSC in patients with AML CR1.

Publiceringsår

2003

Språk

Engelska

Sidor

1119-1124

Publikation/Tidskrift/Serie

Bone Marrow Transplantation

Volym

32

Issue

12

Dokumenttyp

Artikel i tidskrift

Förlag

Nature Publishing Group

Ämne

  • Hematology

Nyckelord

  • haematopoietic stem cell mobilisation
  • G-CSF
  • AML
  • chemotherapy

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1476-5365